Regorafenib (BAY 73-4506) binds to and inhibits VEGFR-1, - 2 and -3, and tumor cell signaling kinases (RET, KIT, PDGFR, and Raf), which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Here, FLT1 is linked to neoplasm.